ReviewFrontiers in pharmacology2026
Peptide-based therapeutics targeting GPCRs: recent applications in the treatment of metabolic disorders.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
G protein-coupled receptors are among the largest protein superfamilies in the human genome and are responsible for sensing diverse extracellular signals and mediating them into cellular responses. Owing to their broad range of subunits and downstream effectors regulated by specific ligands, these receptors have been appealing pharmacological targets for the discovery of new drugs. Peptide agonists emerged as compelling treatment options for metabolic disorders, and many are currently used in therapy. This perspective comprehensively summarizes the medicinal chemistry efforts over the past 5 years toward the discovery of novel agonists targeting G protein-coupled receptors as promising, life-changing peptide therapies to treat metabolic disorders, like obesity and diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.